Harrow (HROW) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$0.46
- Estimate
- -$0.24
- Surprise
- -91.7%
- Revenue (period 2026-06-30)
- $70.7M
- Score today
- 5.0/10
Revenue source: xbrl.
How the report landed
Harrow (HROW) reported a wider loss than forecast — adjusted EPS of -$0.46 against the -$0.24 estimate (a 91.7% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates HROW Sell at 5.0/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's -91.7% surprise compares with a -61.5% four-quarter average. Next scheduled report: 2026-11-09.
What argues against it
- Quality below floor (3.3 < 4.0)
- Momentum score 1.8/10 — below 4.5 minimum
- Death cross — 50-day MA below 200-day MA
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $27.24
- Price target
- $56.55
- Stop
- $26.15
- Upside to target
- +107.6%
- Reward-to-risk
- 10.8:1
Risk check: RSI 6 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-10-15 — shown for context, not personalized investment advice.
HROW at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $1.02B
- P/E (fwd)
- 9.8
- 52-week range
- $26.96–$54.85
- Off 52-week high
- 50.3%
- RSI (14)
- 6
- Volume vs avg
- 0.99×
- Score today
- 5.0/10